Full Title
A Phase I Dose Finding and Phase II Randomized Trial of Iadademstat Combined with Immune Checkpoint Inhibition Maintenance After Initial Chemoimmunotherapy in Patients with Extensive-Stage Small Cell Lung Cancer (NCI 10629) (CIRB)Purpose
Atezolizumab and durvalumab are standard drugs used to treat small cell lung cancer (SCLC). Researchers want to see if adding iadademstat to standard treatment helps slow SCLC growth longer than standard immunotherapies alone. The people in this study have SCLC that spread outside the lung or to other parts of the body.
Immunotherapies helps the body’s immune system find and kill cancer cells. Iadademstat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
If you join this study, you will get iadademstat with your standard treatment (atezolizumab or durvalumab). Researchers are also finding the best dose of iadademstat to use. Iadademstat is taken orally (by mouth) and atezolizumab and durvalumab are given intravenously (by vein).
Who Can Join
To join this study, there are a few conditions. You must:
- Have extensive-stage SCLC.
- Have been treated with platinum etoposide chemotherapy plus either atezolizumab or durvalumab immunotherapy for 4 cycles. This treatment must have made your cancer shrink or stop growing.
- Be able to walk and do routine activities for more than half the time you are awake.
- Be age 18 or older.
Contact
For more information or to see if you can join this study, please call Dr. Charles Rudin’s office at 646-608-3788.